

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

CD16 PE CE

RRID:AB_2868628

Type: Antibody

Proper Citation

BD Biosciences Cat# 332779, RRID:AB_2868628

Antibody Information

URL: http://antibodyregistry.org/AB_2868628

Proper Citation: BD Biosciences Cat# 332779, RRID:AB_2868628

Target Antigen: CD16 (FcγRIII)

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD16 PE CE

Description: This monoclonal targets CD16 (FcγRIII)

Target Organism: human

Clone ID: B73.1

Antibody ID: AB_2868628

Vendor: BD Biosciences

Catalog Number: 332779

Record Creation Time: 20250819T231140+0000

Record Last Update: 20250820T043527+0000

Ratings and Alerts

No rating or validation information has been found for CD16 PE CE.

No alerts have been found for CD16 PE CE.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Munoz-Couselo E, et al. (2025) Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Cancer research communications, 5(2), 358.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell, 187(11), 2817.

Hansen AR, et al. (2024) Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(24), 5540.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. Journal of translational medicine, 21(1), 506.

Roschewski M, et al. (2023) Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3301.